Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VioQuest Pharmaceuticals has announced that the US Patent and Trademark Office has issued a patent for the company's investigational product candidate Xyfid.
Subscribe to our email newsletter
The patent includes pharmaceutical compositions, methods of treatment, and combination kits. The patent applies to the use of Xyfid as well as to a range of methods designed to protect body tissue from the toxic effects of certain systemically administered anticancer therapeutic agents.
Michael Becker, president and CEO of VioQuest, said: “The Xyfid patent further positions VioQuest to advance clinical programs involving Xyfid and new research involving a range of methods to address toxicity issues for patients treated with anticancer therapies in the years ahead.”